Nagar S, Patel J, Stanford RH. Characteristics and health care resource use of subjects with COPD in the year before initiating LAMA monotherapy or LAMA+LABA combination therapy: a U.S. database study. Manag Care. 2018 May;27(5):40-7.
Montserrat-Capdevila J, Godoy P, Marsal JR, Barbe F. Predictive model of hospital admission for COPD exacerbation. Resp Care. 2015 Sep;60(9):1288-94. doi: 10.4187/respcare.04005
Wolowacz SE, Petrillo J, Doward LC, Briggs A. Measuring health-state utility values in clinical trials: can we do better? Ispor Connections. 2014 Sep;20(5):4-8.
Stull DE, Houghton KF, Petrillo J. Innovative data analysis for demonstrating product value: analysis of heterogeneity in treatment response in clinical trials. Ispor Connections. 2013;19(1):5-8.
Masters E, Zlateva G, Harris NI. Real-world data for use in the real world: the pain paradigm. Ispor Connections. 2013;19(2):9-11.
Meyers J, Candrilli S, Allen R, Manjunath R, Calloway M. Health care resource utilization and costs associated with restless legs syndrome among managed care enrollees treated with dopamine agonists. Manag Care. 2012 Oct 1;21(10):44-51.
Dalal AA, Candrilli SD, Davis KL. Outcomes and costs associated with initial maintenance therapy with fluticasone propionate-salmeterol xinafoate 250 ?g/50 ?g combination versus tiotropium in commercially insured patients with copd. Manag Care. 2011 Aug 1;20(8):46-55.
Iyer S, Davis KL, Candrilli S. Opioid use patterns and health care resource utilization in patients prescribed opioid therapy with and without constipation. Manag Care. 2010 Mar 1;19(3):44-51.
Wolowacz SE, Khan SB. The New National Institute of Health and Clinical Excellence (NICE) Single Technology Appraisal (STA) process: experience from the first completed appraisals. Ispor Connections. 2007;13(2):12-5.
Mansfield CA. A consistent method for calibrating contingent value survey data. South Econ J. 1998;64(3):665-81.